SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach record highs amid speculation around potential Fed rate cuts and escalating global trade tensions. The community is actively debating whether this rally signals the beginning of a massive gold run or if a sharp pullback is imminent, with some questioning if gold is overbought while others point to strong central bank buying.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amidst discussions around potential market distribution near all-time highs and reactions to political news. Community members are debating the significance of high daily volumes and whether a significant market correction is imminent. Some traders are expressing concern over recent price action, while others remain bullish, anticipating a rally.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is trending due to a dilutive equity offering announcement, sparking debate about its impact on the share price. While some community members anticipate a price floor and long-term revaluation, others are wary, drawing comparisons to past offerings and predicting a price drop. Analysts remain largely bullish on the stock's long-term potential.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions surrounding political topics, ranging from healthcare and illegal immigration to tariffs and potential government shutdowns. Community members are actively debating the implications of certain policies and events, often leading to heated exchanges and comparisons to past administrations. The stock's performance is also being scrutinized, with some users expressing skepticism about its long-term viability and others pointing to potential catalysts such as Bitcoin holdings and buyback programs.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI Life Sciences is trending due to positive Phase 2a clinical trial results for BPL-003, a treatment for resistant depression, with discussions centering on its potential for FDA approval and market impact. Community members are weighing the implications of a proposed public offering amidst the positive news, with some viewing it as a buying opportunity after the initial volatility. The stock is also gaining attention as part of a broader sector movement towards psychedelic-assisted therapies for mental health.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending due to takeover speculation, with Datadog reportedly exploring a fresh bid. The community is debating the potential deal's value, with some shareholders believing the company is worth significantly more. Meanwhile, some traders express skepticism about the long-term potential of the stock, regardless of takeover news.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers is trending following a strong earnings report, with discussions focusing on the company's growth in customer accounts and trading activity. Community members are weighing the impact of potential interest rate cuts on future earnings, while analysts are raising price targets. Some traders believe the stock is undervalued and poised for further gains, while others note potential headwinds.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community sentiment turns bearish despite a potential $70 price target from HSBC, with traders citing frustration over the stock's underperformance relative to competitors like Eli Lilly. Recent news, including cost-cutting measures and a $4.7B acquisition of Akero Therapeutics to diversify beyond GLP-1 drugs, is fueling debate about management's strategic direction and the company's growth prospects. Some investors express concerns about competition and pricing pressures, while others maintain a bullish long-term outlook, anticipating positive catalysts from FDA approvals and Alzheimer's drug trials.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending due to recent volatility and speculation around potential government investment in rare earth minerals, driven by renewed focus on domestic supply chains. The community is actively discussing the stock's price swings, potential short squeezes, and the impact of European Lithium's (EULIF) stake in the company. Many are also closely watching for news related to President Trump's upcoming meeting with the Australian Prime Minister, which could involve critical minerals discussions.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending downwards, sparking frustration and concern among the community regarding market manipulation and lack of upward momentum. While some investors express long-term bullish sentiment, others are losing patience, questioning the utility and future prospects of XRP. Discussions include potential ETF approvals, government regulations, and broader market factors influencing price action.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sol-Gel Technologies (SLGL) were in the spotlight on Friday morning after the company’s first-quarter (Q1) revenue dipped below Wall Street expectations, and losses came in wider-than-expected.The company, which is focused on developing drugs for skin diseases, <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-reports-first-quarter-2025-results">reported</a> total revenue of $1 million in the quarter, compared to $0.5 million for the same period in 2024, but below an analyst estimate of $1.2 million, as per FinChat data.Diluted loss per share came in at $3.2, compared to a loss of $2.3 per share for the same period in 2024, and exceeding an estimated loss of $1.2.The company’s research and development expenses soared in the three months through the end of March by 65% year-on-year to $8.8 million.Sol-Gel ended the quarter with $16.9 million in cash, cash equivalents, and deposits. The company expects the cash resources to fund its requirements into the first quarter of 2027.Sol-Gel has two FDA-approved drugs—TWYNEO for treating acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY for treating inflammatory lesions of rosacea in adults.The company is testing a drug candidate for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and another for the treatment of rare skin keratodermas.Earlier this month, Sol-Gel announced a reverse share split at the ratio of 10-for-1 to increase its share price and regain compliance with requirements for continued listing on the exchange.On Stocktwits, retail sentiment around Sol-Gel stayed unchanged within the ‘bearish’ territory over the past 24 hours, coupled with ‘extremely low’ message volume.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_9_39_02_AM_png_3d341c467c.webp" alt="SLGL's Sentiment Meter and Message Volume as of 9:40 a.m. ET on May 23, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>SLGL's Sentiment Meter and Message Volume as of 9:40 a.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/SLGL">SLGL stock</a> is down by about 25% this year and 5% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/trump-coin-gala-dinner-tells-crypto-backers-biden-made-your-lives-miserable/ch0QkElRbqY">Trump Coin Gala Dinner Highlights: US President Tells Crypto Backers Biden ‘Made Your Lives Miserable,’ Promises Relief</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

The company’s diluted loss per share came in at $3.2, exceeding an estimated loss of $1.2.

Equity

The company’s diluted loss per share came in at $3.2, exceeding an estimated loss of $1.2.


Sol-Gel Technologies Announces Key Shareholder Decisions

Sol-Gel Technologies (SLGL) has released an update. Shareholders of Sol-Gel Technologies Ltd., a company based in Ness Ziona, Israel, have recently...

Sol-Gel Announces Executive Changes Amid Growth

Sol-Gel Technologies (SLGL) has released an update. Sol-Gel Technologies, a dermatology company known for its innovative skin treatments and FDA-ap...

Sol-Gel Technologies Announces Leadership Changes

Sol-Gel Technologies (SLGL) has released an update. Sol-Gel Technologies Ltd., an innovative dermatology company, announced a management realignmen...

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve  Cream

Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments...

Sol-Gel Technologies collaboration partner first-to-file ANDA generic to Zoryve

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sol-Gel Technologies: Q4 Earnings Insights

Sol-Gel Technologies reports 2023 EPS ($1.01) vs. (65c) last year

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025...

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$40.51
Prev Close	$41.76
Open	$42.75
Dividend Yield	0.00%
50-Day Moving Average	$26.18
Beta	0.48
Avg. Volume	21,536.95
PE Ratio	-34.11

52-Week High	$52.26
52-Week Low	$4.01
Market Capitalization	$116.33M
EPS (Annual)	-$3.80
Price to Book	3.65
Revenue Per Employee	$339,352.94
Enterprise Value/EBITDA	N/A

SLGL
Sol-Gel Technologies Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLGL News

SLGLSol-Gel Technologies Ltd